Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization.

GÖREK DİLEKTAŞLI A., Cetinoglu E., Uzaslan E., BUDAK F., COŞKUN N. F., URSAVAŞ A., ...Daha Fazla

International journal of chronic obstructive pulmonary disease, cilt.12, ss.199-208, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.2147/copd.s118424
  • Dergi Adı: International journal of chronic obstructive pulmonary disease
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.199-208
  • Anahtar Kelimeler: COPD, frequent exacerbator, hospitalized exacerbation, PARC/(CCL-18), OBSTRUCTIVE PULMONARY-DISEASE, SYSTEMIC INFLAMMATION, LUNG-FUNCTION, BIOMARKERS, FREQUENCY, CCL18, MACROPHAGES, VALIDATION, PHENOTYPES, DYSPNEA
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Introduction: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization.